31 related articles for article (PubMed ID: 30797782)
1. Hotoda's Sequence and Anti-HIV Activity: Where Are We Now?
Romanucci V; Zarrelli A; Di Fabio G
Molecules; 2019 Apr; 24(7):. PubMed ID: 30974914
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, Biophysical Characterization, and Anti-HIV-1 Fusion Activity of DNA Quadruplex-based Inhibitors with Dipeptide MT Hook Conjugation.
Xu L; Han Z; Ren H
Curr HIV Res; 2021; 19(4):317-323. PubMed ID: 33902414
[TBL] [Abstract][Full Text] [Related]
3. A novel multivalent DNA helix-based inhibitor showed enhanced anti-HIV-1 fusion activity.
Tang Y; Han Z; Ren H; Guo J; Chong H; Tian Y; Liu K; Xu L
Eur J Pharm Sci; 2018 Dec; 125():244-253. PubMed ID: 30292749
[TBL] [Abstract][Full Text] [Related]
4. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
5. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
6. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
7. DNA Quadruplex-Based Inhibitor With Flexible Fragments at the 3' Terminal Shows Enhanced Anti-HIV-1 Fusion Activity.
Han Z; Tang Y; Ren H; Liu K; Xu L
J Pharm Sci; 2019 Jul; 108(7):2243-2246. PubMed ID: 30797782
[TBL] [Abstract][Full Text] [Related]
8. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 by fusion inhibitors.
Eggink D; Berkhout B; Sanders RW
Curr Pharm Des; 2010; 16(33):3716-28. PubMed ID: 21128887
[TBL] [Abstract][Full Text] [Related]
11. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).
Zhang D; Li W; Jiang S
Expert Opin Ther Pat; 2015 Feb; 25(2):159-73. PubMed ID: 25428639
[TBL] [Abstract][Full Text] [Related]
12. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
